Multiple Sclerosis News Today Forums › Forums › COVID-19 and MS › FDA Approves Zeposia (Ozanimod) to Treat RRMS, Active SPMS and CIS

  • COVID-19 and MS

    FDA Approves Zeposia (Ozanimod) to Treat RRMS, Active SPMS and CIS

    Posted by ms-news-today-moderator on March 31, 2020 at 11:03 am

    The U.S. Food and Drug Administration approved oral Zeposia for adults with relapsing forms of MS, but its arrival in clinics is delayed due to COVID-19. Read the full story here.

    How do you feel about this news? What other news stories have you read about the impact of COVID-19 on MS treatments and clinics?

    ms-news-today-moderator replied 4 years ago 0 Member · 0 Replies
  • 0 Replies

Sorry, there were no replies found.

Log in to reply.

Start of Discussion
0 of 0 replies June 2018
Now

Report

Harassment or bullying behavior
Contains mature or sensitive content
Contains misleading or false information
Contains abusive or derogatory content
Contains spam, fake content or potential malware

Block Member?

Please confirm you want to block this member.

You will no longer be able to:

  • See blocked member's posts
  • Mention this member in posts
  • Invite this member to groups
  • Message this member
  • Add this member as a connection

Please note: This action will also remove this member from your connections and send a report to the site admin. Please allow a few minutes for this process to complete.

Report

You have already reported this .